FindTrial
Sign In

A study comparing the effectiveness of two ointments, Tacrolimus and Calcipotriol, used along with handheld narrow band UVB light therapy in improving white patches (vitiligo) on the skin.

Comparision on efficacy of topical Tacrolimus 0 point 1 percent ointment with handheld narrow band ultraviolet B versus topical Calcipotriol 0 point 005 percent ointment with handheld narrow band ultraviolet B in treatment of vitiligo a randomized controlled study - NIL

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2025/11/097982
Enrollment
58
Registered
2025-11-24
Start date
Unknown
Completion date
Unknown
Last updated
2025-12-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: L80- Vitiligo

Interventions

Intervention1: Topical Tacrolimus 0.1 percent ointment with handheld narrow band ultraviolet B: Participants in Group A will receive topical Tacrolimus 0.1 percent ointment, applied twice daily over v

Sponsors

PONNAGANTI PARVATHI ANNAPURNA
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Patients clinically diagnosed with vitiligo. Age above six years. Body surface area involvement less than twenty percent. Willing to provide written informed consent or assent for minors.

Exclusion criteria

Exclusion criteria: Not willing to participate. Pregnant or lactating women. Other autoimmune dermatological disorders. Allergy to tacrolimus or calcipotriol. Photosensitivity or contraindication to phototherapy.

Design outcomes

Primary

MeasureTime frame
The primary outcome of the trial is the percentage of repigmentation area in vitiligo patients, which is assessed using the VASI (Vitiligo Area Scoring Index) scoreTimepoint: The outcomes are evaluated at multiple timepoints during the study, but the most specific timepoint of primary interest appears to be the 3 months follow-up after initiating treatment—

Secondary

MeasureTime frame
Documentation and assessment of adverse effects such as erythema, edema, itching, hypertrichosis, and acne-like papules.Evaluation of improvement by independent, blind third-party assessment using the Global Photographic Assessment (GPA) scale.The mean improvement in the VASI score by the physician (Mean Improvement Score by Physician, MISP).Timepoint: 3 MONTHS FOLLOW UP—

Countries

India

Contacts

Public ContactPONNAGANTI PARVATHI ANNAPURNA

SRI DEVARAJ URS MEDICAL COLLEGE

sbmurugesh@hotmail.com9880399499

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026